Summary of the Conference Call for Zhaoyan New Drug (March 31, 2023) Company Overview - **Company**: Zhaoyan New Drug - **Industry**: Biopharmaceuticals and Laboratory Services Key Financial Highlights - **Net Profit**: 2025 net profit attributable to shareholders is projected at 298 million yuan (+302.08%), primarily due to the increase in experimental monkey prices contributing 476 million yuan in fair value changes [2][4] - **Revenue**: Total revenue for 2025 is 1.658 billion yuan, with domestic customers contributing 1.204 billion yuan (72.65%) and international customers 453 million yuan (27.35%) [4] - **Gross Profit**: Gross profit for 2025 is 343 million yuan, with a gross margin of 20.71%, impacted by intensified market competition leading to price declines [4][5] - **Operating Cash Flow**: Operating cash flow for 2025 is 445 million yuan, up 31.17% year-on-year, providing a solid financial foundation for innovation and expansion [5] Order and Market Dynamics - **New Orders**: New signed orders for 2025 reached 2.6 billion yuan (+41.3%), with Q4 alone contributing 960 million yuan (+118.18%) [2][5] - **Order Backlog**: As of the end of 2025, the order backlog totals 2.6 billion yuan, reflecting an 18.18% year-on-year increase [5] - **Price Recovery**: By Q4 2025, over 50% of new orders' growth was attributed to price increases, with expectations for significant gross margin improvement starting Q4 2026 [2][6] Supply Chain and Capacity - **Experimental Monkey Supply**: The supply of experimental monkeys remains tight, with prices expected to rise further in Q1 2026. The company is ensuring supply through its own monkey farms and cautious evaluation of imports [2][8] - **Capacity Expansion**: The company has expanded its capacity with a new 20,000 square meter facility in Suzhou and plans for a large facility in Guangzhou expected to be operational by 2027 [3][7] Technological Advancements - **Technological Focus**: The company has been developing organoid technology for 5-6 years, focusing on liver and heart applications. AI is being utilized in pathology to enhance efficiency [3][18] - **Clinical Services**: Although currently a small revenue contributor, the clinical services segment has gained experience in gene therapy and traditional therapies, with plans to secure more orders in 2026 [16] Market Outlook - **2026 Projections**: The company anticipates continued strong order growth in 2026, with a high double-digit increase expected. However, revenue and profit improvements may lag due to the timing of order confirmations [2][13] - **Price Trends**: The pricing for large animal experiments has returned to pre-adjustment levels, while small animal and canine experiment prices are still recovering [6][11] Challenges and Risks - **Import Challenges**: The import of experimental monkeys faces challenges, including finding reliable suppliers and limited quarantine facilities in China [12][17] - **Market Volatility**: The company is cautious about the potential risks associated with imported monkeys and is focused on maintaining quality standards [10] Conclusion Zhaoyan New Drug is positioned for growth with strong order momentum and a focus on technological advancements. However, challenges in supply and market conditions may impact short-term financial performance. The company is strategically planning for capacity expansion and technological integration to enhance its competitive edge in the biopharmaceutical industry.